Shanghai, January 12, 2020 – Laekna Therapeutics, a clinical-stage biotech company focused on innovative drug development and discovery, today announced that it has scheduled a company presentation at Biotech Showcase™ 2020, to be held January 13–15, during the most important week in healthcare at the Hilton San Francisco Union Square.
Dr. Chris Lu, the founder and CEO of Laekna, will be presenting an update on Laekna’s business strategy and the progress of its clinical programs including afuresertib, an AKT inhibitor, at Biotech Showcase as follows:
Date: Wednesday, January 15 2020
Time: 11:00AM (PST)
Room: Franciscan C (Ballroom Level)
Venue: Hilton San Francisco Union Square Hotel, 333 O’Farrell Street, San Francisco, CA (United States)
Laekna currently has three clinical stage oncology candidates in-licensed from Novartis covering targeted, anti-hormone, and immune therapies. These compounds have been extensively studied previously in a number of phase I & II clinical trials and have demonstrated excellent anti-cancer activities and tolerable safety profiles.
"We are excited to present the progress of our clinical programs at Biotech Showcase™," said Dr. Chris Lu. “This will be a good opportunity to introduce Laekna’s key clinical programs to pharmaceutical community. We are actively seeking opportunities to collaborate with potential investors and business partners and quickly advance the programs through the clinical stage to help patients."
Biotech Showcase, produced by Demy-Colton and EBD Group, is an investor conference focused on driving advances in therapeutic development by providing a sophisticated networking platform for executives and investors that fosters investment and partnership opportunities. The conference takes place each year during the course of one of the industry's largest gatherings and busiest weeks.
“We are delighted that Laekna Therapeutics will be presenting at Biotech Showcase this year,” said Sara Demy, CEO of Demy-Colton. “Biotech Showcase is a prime occasion for life science entrepreneurs and investors to come together to discover the potential of innovative technologies that will drive the future of drug discovery.”
ABOUT BIOTECH SHOWCASE
Biotech Showcase is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place. Investors and biopharmaceutical executives from around the world gather in San Francisco during this bellwether week which sets the tone for the coming year. Now in its 12th year, this well-established, highly respected conference features multiple tracks of presenting companies, plenary sessions, workshops, networking, and an opportunity to schedule one-to-one meetings. Biotech Showcase is produced by Demy-Colton and EBD Group. Both organizations have a long history of producing high-quality programs that support the biotechnology and broader life sciences industry.
ABOUT LAEKNA THERAPEUTICS
Laekna Therapeutics is an innovative company dedicated to the development of new generations of small molecule and antibody-targeted drugs, and focused on developing new targeted therapies to treat cancer and liver diseases. Laekna has developed an innovative R&D pipeline based on disease causative biological mechanisms and molecular pathways, producing innovative new first-in-class and best-in-class drugs. Laekna Therapeutics continues R&D into their own in-house projects, developing new breakthrough drugs to benefit more patients, and building an internationally influential drug R&D platform.
For additional information on Laekna, please visit: https://www.laeknatp.com.
Contacts
Investor Relations:
Dr. Chris Lu
Media Contact: